Myocardial Ischemia Clinical Trial
— EVAOfficial title:
Sex and Gender Differences in Ischemic Heart Disease: From Bench to Bedside EVA (Endocrine Vascular Disease Approach)
NCT number | NCT02737982 |
Other study ID # | RBSI14HNVT |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | September 2020 |
Verified date | November 2020 |
Source | University of Roma La Sapienza |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The application of sex-gender medicine is strongly recommended by World Health Organization and other international organization. In fact, it is emerging that, although men and women are affected to the same cardiovascular diseases (CVD), however they have different risk factors, disease progression and response to pharmacological and not-pharmacological treatments. Consequentially, the identification of biomarkers and therapeutic approaches taking into account sex gender differences (SGD) is relevant to develop a really evidence-based medicine. With the aim of translate in clinical setting the more recently available basic research evidences on estrogens and androgens balance involvement in modulation of ischemia-reperfusion myocardial damage, the investigators planned to conduct a research study on patients, affected by suspected or known ischemic heart disease (IHD) undergoing angiography and/or percutaneous coronary interventions (PCI), aged more than 18 years of both sex in ratio 1:1. Thus, in this setting, the goals of this proposal are: 1. To assess the sex-gender difference in entity of microvascular reperfusion damage in patients with IHD undergoing urgent or elective PCI; 2. To evaluate estrogen/androgen-dependent and -independent effects in gender-related differences on myocardial ischemia reperfusion damage occurring during PCI; 3. To investigate the differences in terms of platelet biology between men and women affected by IHD undergoing urgent or elective PCI, matched for age and clinical cardiovascular and metabolic characteristics; 4. To verify sex-driven interplay between response to PCI procedure, platelet function, sex hormones and entity of reperfusion and myocardial damage, as well as, the impact on clinical outcomes during a 1-year follow up. This research study wants to explore and consequently elucidate biological mechanisms responsible for sex-based differences in vivo human models of ischemia reperfusion myocardial damage. Moreover, the investigators expected to clarify the impact of biological variables evaluated on clinical outcomes after reperfusion therapeutic intervention.
Status | Completed |
Enrollment | 509 |
Est. completion date | September 2020 |
Est. primary completion date | March 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - patients with ischemic heart disease (acute or chronic) undergoing percutaneous coronary intervention (urgent or elective) - written informed consent - both sex - aged more than 18 years Exclusion Criteria: - patients with expectancy of life less than 12 months - active cancer - pregnancy |
Country | Name | City | State |
---|---|---|---|
Italy | Policlinico Umberto I , Sapienza University of Rome | Rome |
Lead Sponsor | Collaborator |
---|---|
University of Roma La Sapienza | Ministry of Education, Universities and Research, Italy |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of corrected Thrombolysis In Myocardial Infarction frame count and myocardial blush grade | angiographic assessment of coronary flow | baseline; within 1h from PCI | |
Secondary | Sexual hormones levels in patients with IHD undergoing PCI | Evaluation and impact of sexual hormones levels in gender-related differences during myocardial reperfusion | baseline | |
Secondary | Platelet activation markers including Thromboxane, soluble cluster designation 40 (CD40) Ligand and soluble P-selectin in patients with IHD undergoing PCI | Evaluation of Sex and gender differences in platelet function | baseline; within 1h from PCI; 12 months | |
Secondary | Clinical outcomes including cardiovascular mortality, re-hospitalization and restenosis | 12 months | ||
Secondary | Microvascular dysfunction assessed by cardiac magnetic resonance | Among the EVA registry, we plan to perform a pilot study including: patients with stable angina with mono-vessel obstructive coronary artery disease (CAD) undergoing PCI; patients with stable angina undergoing angiography that documented no obstructive coronary disease (with a stenosis <50%) with a impairment of microvascular dysfunction defined during angiography by a myocardial blush grade <2 or coronary flow reserve <2 after stress stimulus. | 7 days from percutaneous coronary intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Active, not recruiting |
NCT04555174 -
BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
|
||
Recruiting |
NCT04582877 -
Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial
|
N/A | |
Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
Recruiting |
NCT03265535 -
Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
|
||
Not yet recruiting |
NCT04522583 -
Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
|
||
Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
Terminated |
NCT02407626 -
Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery
|
N/A | |
Active, not recruiting |
NCT02189499 -
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
|
Phase 2 | |
Completed |
NCT02197065 -
Pilot Study of Atorvastatin for Orthopedic Surgery Patients
|
Phase 2 | |
Completed |
NCT02264717 -
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Terminated |
NCT01892917 -
BIOFLOW-III Hungary Satellite Registry
|
N/A | |
Completed |
NCT01655043 -
Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
|
Phase 2 | |
Completed |
NCT01679886 -
Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women
|
N/A | |
Completed |
NCT02707445 -
Genotyping Influences Outcome of Coronary Artery Stenting
|
N/A |